Displaying 25 - 36 of 45
Viral Hepatitis
4

AbbVie: How Can We Accelerate HCV Elimination in the Current Landscape? - Digital ILC 2020

View
Immune-Mediated and Cholestatic Diseases
1

Albireo: Challenges in the Management of Patients with Cholestatic Liver Diseases - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
4

Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
General Hepatology
6

Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020

View
Displaying 25 - 36 of 45